drugset / Trial / NCT01282619

Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease

NCT01282619

Phase 2/3 Unknown 390 enrolled Shandong Luye Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The main purpose of this study is to evaluate the safety and efficacy of Huperzine A sustained release tablets in patients with mild to moderate Alzheimer's Disease.

Timeline

Start
2010-05
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Huperzine A Traditional medicine (herbal / TCM) 200 ug
Subject Huperzine A Traditional medicine (herbal / TCM) 400 ug

Indications